SCHON KLINIK BAD AIBLING SE & CO KG

Their core work

Schön Klinik Bad Aibling is a German private rehabilitation clinic specializing in neurological recovery, particularly for patients with disorders of consciousness and complex brain injuries. Within EU research, they serve as a clinical partner providing real-world patient environments for testing rehabilitation technologies — from exoskeletons and digital twins to affective computing systems for elderly care. Their value lies in bridging the gap between laboratory prototypes and actual clinical deployment in a functioning hospital setting.

What they specialise in

How they've shifted over time

Their early H2020 work (2016–2018) centered on traditional clinical concerns: elderly healthcare engagement (REACH2020) and evidence-based care for disorders of consciousness (DoCMA), including brain stimulation techniques. From 2019 onward, their focus shifted decisively toward technology-intensive rehabilitation — affective computing, exoskeletons, digital twins, and multi-sensing environments. This trajectory shows a clinic that started as a conventional clinical partner and is increasingly becoming a testbed for advanced rehabilitation technologies.

SKBA is moving from traditional clinical participation toward becoming a living lab for robotic and AI-driven rehabilitation, making them an increasingly attractive partner for medtech innovators needing clinical validation.

How they like to work

SKBA consistently joins as a participant rather than leading consortia, which is typical for clinical partners who contribute patient access, clinical expertise, and validation environments rather than driving the research agenda. With 52 unique partners across 15 countries from just 4 projects, they operate in large, diverse consortia — indicating comfort with complex international collaborations. Their role is that of a trusted clinical site: they don't need to lead, but they bring something few academic labs can offer — real patients in a real hospital.

Despite only 4 projects, SKBA has built connections with 52 distinct partners across 15 countries, reflecting participation in large pan-European consortia. Their network spans Western, Southern, and Central Europe with no narrow geographic concentration.

What sets them apart

As a private rehabilitation clinic (not a university hospital or research institute), SKBA offers something rare in EU consortia: a commercial healthcare facility willing to integrate experimental technologies into actual patient care pathways. Their specialization in neurological rehabilitation — especially disorders of consciousness — puts them in a niche where few clinical partners operate. For any consortium developing rehabilitation robots, brain-computer interfaces, or digital health tools for neurological patients, SKBA provides the clinical reality check that reviewers want to see.

Highlights from their portfolio

• ReHyb
  Their largest project (EUR 568K) combining exoskeletons with digital twin technology for rehabilitation — represents their most advanced technology integration.
• DoCMA
  A Marie Skłodowska-Curie staff exchange project focused on the highly specialized field of disorders of consciousness, signaling deep clinical expertise in this rare condition.
• TeNDER
  Bridges health and digital sectors through affective computing and multi-sensing environments for integrated elderly care — showing SKBA's ability to serve as a clinical testbed for AI-driven care systems.